Archive for July, 2024

Do People with Diabetes Smoke Less on Semaglutide?

July 31, 2024 — A fascinating new study in Annals of Internal Medicine asks an important question. When people receive semaglutide for type 2 diabetes, are they less likely to smoke? This is not such a random question. In fact, clinicians are reporting striking reductions in addictive behaviors by people receiving it for obesity. So William Wang and colleagues […]

What’s Known and Unknown About the UK Sugar Tax Effects

July 30, 2024 — The soft drinks industry levy came into effect in the UK in early 2018. The first study to investigate the effect of this “sugar tax” on individual-level consumption has just been published in the Journal of Epidemiology and Community Health. The headline finding is that adults reduced their daily added sugar intake by about two […]

Trends in Diabetes, Obesity, and Equitable Access to GLP-1s

July 29, 2024 — When the subject of equitable access to GLP-1s arises, contrasting perspectives of what is equitable become apparent. Last week in the Annals of Internal Medicine, an analysis of prescription data for GLP-1 agonists made two facts about their use very clear. First, their use for obesity is growing much faster than the use for type […]

Knots of Like-Minded People Free from Curiosity

July 28, 2024 — It simply feels good to find people who think like we do. We can give voice to strong feelings, we can find validation, and we can join in an amen chorus of affirmation. But unfortunately, we can also get stuck in a dead end – committed to ideas that don’t find acceptance in the real […]

Rising Competition Gets Lilly and Novo Nordisk Down

July 27, 2024 — It’s been a rough month for investors in Lilly and Novo Nordisk – largely because of the prospects for rising competition to their wildly successful obesity medicines. Accelerating VK2735 This week, Viking Therapeutics announced they are accelerating development of injectable form of VK2735, a dual agonist that works on both GLP-1 and GIP receptors. This […]

Will GLP-1s Level the Field in an Obesogenic Environment?

July 26, 2024 — The rousing success of GLP-1 medicines for obesity and overweight evokes a wide range of feelings. At the National Academy of Sciences this week we heard lamentations from a scholar in exercise physiology. To him, these highly effective treatments are a distraction from the importance of focusing in healthy eating and active living. We hear […]

10 Years of Obesity Solutions at the National Academy of Sciences

July 25, 2024 — It has been ten years that diverse stakeholders have been meeting at the National Academy of Sciences in the Roundtable on Obesity Solutions. In our role as advisor to the Obesity Society, we participated in a symposium at the Academy focused on looking back and moving forward. A Fraught History of “Solutions” For looking back, […]

Wrestling with BMI in the Annals of Internal Medicine

July 24, 2024 — It’s nice, really. People are paying attention to obesity, its definition, and the bias they bring to the subject. If you need evidence of this, look no further than a series of three new editorials in the Annals of Internal Medicine. They’re wrestling with BMI and the definition of obesity. The authors present a range […]

MASLD and MASH: Unknown Risks of Obesity and Diabetes

July 23, 2024 — Liver disease is frighteningly common worldwide. Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a buildup of fat in the liver. Formerly known as nonalcoholic fatty liver disease, this condition affects 1 in 4 people worldwide. Among those with type 2 diabetes, insulin resistance, obesity, or all three, […]

The Unfortunate Gray Market for Obesity Medicines

July 22, 2024 — A gray market for obesity medicines is thriving. The quality of the products in this market range from reasonable to sketchy to utterly unreliable. But millions of people are taking a chance on them. Big pharma companies innovated to bring fully vetted formulations of important medicines to market, spending billions of dollars to do it. […]